Atavistik Bio Will Present HHT Drug Research
The company will debut new data on its ATV-1601 therapy for hereditary hemorrhagic telangiectasia this October.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize patient needs when developing new medical treatments?
Cambridge-based Atavistik Bio will showcase research on its drug candidate, ATV-1601, at the Cure HHT 16th International Scientific Conference. The event, held in Cape Cod from October 12-16, 2026, will feature preclinical data and updates on the Harmony-HHT clinical trial.
Why it matters
The company is focused on addressing significant, unmet treatment needs for patients suffering from hereditary hemorrhagic telangiectasia. By advancing the Harmony-HHT study, researchers aim to provide new therapeutic options for those affected by the condition.
ATV-1601 is an oral allosteric inhibitor designed to selectively target AKT1. The drug is currently moving through the Phase 1/2 Harmony-HHT trial.
The players
Atavistik Bio
This biotechnology firm is headquartered in Cambridge and focuses on developing innovative hematology therapeutics.
Cure HHT
This organization is dedicated to finding a cure for hereditary hemorrhagic telangiectasia and supports research initiatives.
The details
Atavistik Bio utilizes a proprietary allosteric discovery platform to develop specialized hematology therapeutics. The upcoming presentations will include a trial-in-progress poster and a plenary session dedicated to clinical progress.
Timeline
October 12-16, 2026: The Cure HHT 16th International Scientific Conference takes place in Cape Cod.
October 13, 2026: The company will hold poster presentations at the conference.
October 14, 2026: A plenary session on the clinical trial will occur.
October 27, 2026: Atavistik Bio will participate in an educational webinar for patients.
The Big Picture
This development marks a milestone in the ongoing progress of the Harmony-HHT clinical trial. The event updates the clinical narrative for this specific research program by sharing preliminary results with the scientific community.
Patients and their families can access critical information regarding the Harmony-HHT study through the upcoming webinar. Understanding these trial phases helps the community track potential future treatment options.
The takeaway
Atavistik Bio is moving its therapeutic candidate closer to standard clinical evaluation for a complex condition. Interested patients are encouraged to use available webinars to stay informed on the evolving research landscape.
What happens next
Atavistik Bio will participate in a patient-focused educational webinar on October 27, 2026.
Further reading
For more news on local life sciences, visit the Biotech section.
More information
To learn more about the upcoming patient webinar, register at the Harmony-HHT clinical trial webinar registration.
Live Poll
Do you trust pharmaceutical companies to prioritize patient needs when developing new medical treatments?
